Pieris Pharmaceuticals, Inc. (PIRS)

$16.27

-0.28

(-1.69%)▲

Market is closed - opens 7 PM, 15 Oct 2024

Performance

  • $16.25
    $16.30
    $16.27
    downward going graph

    0.12%

    Downside

    Day's Volatility :0.31%

    Upside

    0.18%

    downward going graph
  • $6.20
    $23.20
    $16.27
    downward going graph

    61.89%

    Downside

    52 Weeks Volatility :73.28%

    Upside

    29.87%

    downward going graph

Returns

PeriodPieris Pharmaceuticals, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
119.58%
4.7%
0.0%
6 Months
19.64%
11.6%
0.0%
1 Year
-25.99%
18.9%
0.0%
3 Years
-95.49%
20.9%
-21.9%

Highlights

Market Capitalization
21.8M
Book Value
$14.17
Earnings Per Share (EPS)
-19.21
PEG Ratio
0.0
Wall Street Target Price
7.0
Profit Margin
-114.12%
Operating Margin TTM
-56.9%
Return On Assets TTM
-13.18%
Return On Equity TTM
-80.46%
Revenue TTM
20.9M
Revenue Per Share TTM
16.66
Quarterly Revenue Growth YOY
-97.3%
Gross Profit TTM
-27.1M
EBITDA
-11.3M
Diluted Eps TTM
-19.21
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Sell
    0
    0%Buy
    50%Hold
    50%Sell
Based on 6 Wall street analysts offering stock ratings for Pieris Pharmaceuticals, Inc.(by analysts ranked 0 to 5 stars)
Based on 6 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
3
3
3
Sell
3
3
3

Analyst Forecast

What analysts predicted

Downside of 56.98%

Current $16.27
Target $7.00

Technicals Summary

Sell

Neutral

Buy

Pieris Pharmaceuticals, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc.
-0.3%
19.64%
-25.99%
-95.49%
-93.66%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-12.04%
13.03%
20.22%
83.59%
233.83%
Novo Nordisk A/s
Novo Nordisk A/s
-12.51%
-3.12%
18.42%
134.59%
356.57%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
4.79%
92.5%
69.4%
36.33%
250.43%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-0.94%
22.01%
29.63%
166.72%
175.25%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc.
NA
NA
0.0
0.0
-0.8
-0.13
NA
14.17
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.87
26.87
1.38
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.83
40.83
1.84
3.37
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.43
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.58
0.33
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc.
Sell
$21.8M
-93.66%
NA
-114.12%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$111.9B
233.83%
26.87
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$535.2B
356.57%
40.83
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$36.5B
250.43%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$125.1B
175.25%
32.84
-4.74%

Insights on Pieris Pharmaceuticals, Inc.

  • Decreasing Revenue

    Revenue is down for the last 4 quarters, 20.05M → 53.0K (in $), with an average decrease of 64.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -4.89M → -3.59M (in $), with an average increase of 36.3% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 68.5% return, outperforming this stock by 96.8%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 35.8% return, outperforming this stock by 131.3%

Institutional Holdings

  • Bvf Inc

    19.51%

  • BlackRock Inc

    0.98%

  • Renaissance Technologies Corp

    0.87%

  • Vanguard Group Inc

    0.86%

  • Geode Capital Management, LLC

    0.80%

  • UBS Group AG

    0.13%

Company Information

pieris pharmaceuticals is a clinical stage biotechnology company that discovers and develops anticalin-based drugs to target validated disease pathways in a unique and transformative way. our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled anticalin to treat uncontrolled asthma and a half-life-optimized anticalin to treat anemia. proprietary to pieris, anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. our libraries of more than 100 billion different anticalin proteins have repeatedly delivered drug candidates binding to a very broad spectrum of therapeutic targets. pieris has established a diverse pipeline of anticalin therapeutics for a number of different indications and has r&d collaborations with roche

Organization
Pieris Pharmaceuticals, Inc.
Employees
46
CEO
Mr. Stephen S. Yoder J.D.
Industry
Health Technology

Discover More

FAQs